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With April 1991 heralding in what are arguably the most
major changes ever in the NHS, palliative care services, as
with all other aspects of health care, are being 'provided' and
'purchased', against the background of defined service
specifications ('business plans') and agreed 'contracts'. Such
terminology would, just 5 years ago, have been unheard of or
even thought heretical, by clinical carers in this often emotive
and 'public spirited' field. Such attitudes were heightened by
the tendency of health care professionals to arbitrarily
separate off 'palliative' care from general cancer treatment
services; palliative care took over after the failure of or
absence of specific oncological treatment. Such a situation
could not be to the benefit of patients; whilst researching the
underlying causes and possible curative treatments is a fun-
damental role for oncologists, it is not true that they are 'just
interested in finding a cure for cancer; a foolhardy and costly
exercise which diverts them and resources from more cost
effective areas'. Indeed more than half of their work load is
concerned with the relief of symptoms by radiotherapy and/
or chemotherapy. Neither are palliative care physicians moti-
vated only by a wish to help their patients die comfortably!
The term continuing care is sometimes used to encompass the
multidisciplinary aspects of cancer management from diag-
nosis to cure or palliation or to death, and this is a useful
concept in the overview of cancer care services as a whole.
Part of the role of oncologists affiliated to District General
hIospitals must be to provide an on-site specialist service
potentially accessible to all patients at any stage of their
illness (Rees et al., 1991).
The benefits of cancer treatment are longer survival, relief
of symptoms or both. Treatment may be unpleasant and
costs must be taken into account (Rees, 1985; Markman,
1988). Potentially curative and adjuvant therapies, if assessed
as cost for each year of benefit obtained, are good value for
money - generally less than £1000 per year per patient
(Rees, 1991). For example, taking into account all costs
(chemotherapy, radiotherapy, hospital care, investigations
etc) the average patient-benefit-year cost in advanced Hodg-
kin's Disease is approximately £450 and for adjuvant CMF
(Cyclophosphamide, Methotrexate, Fluorouracil) in localised
breast cancer £400. Active palliative treatments, which are
often relatively more expensive than 'best supportive care',
need to be effective but must also use resources appropriately
(Rubens, 1990) - long courses of radiotherapy or high cost
or prolonged chemotherapy regimens (which are not part of
an evaluated trial), particularly in-patient, usually achieve no
better results than shorter, less expensive treatments (e.g.
Price et al., 1986; Spiro & Souhami, 1990). As a specific
example a recent MRC prospective randomised trial showed
that a two-treatment radiotherapy regimen was as safe,
tolerable and effective as a more prolonged (10 fraction)
treatment in palliating symptoms (MRC Lung Cancer Work-
ing Party, 1991). Resources may be better used in increasing
consultation time and multidisciplinary care. Hower, eco-
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nomic evaluation of various treatment options is complex
and palliative chemotherapy particularly should not just be
dismissed as inappropriately expensive; the costs of the drugs
used and the in-patient, out-patient, and home care required
must all be assessed, and compared with those of 'best
supportive care' where, for example, more time may be spent
by the patient in hospital than when having active treatment
(Jaakkimainen et al., 1990). Also, in non-specialist hands the
approach to palliative anti-cancer treatment may be very
nihilistic; 'more' may not be better but 'less' is sometimes
inadequate. For example, continuous chemotherapy is better
than intermittent chemotherapy for advanced breast cancer
(Coates et al., 1987). Dedicated oncologists should be avail-
able to advise in such situations and consensus guidelines for
the management of common cancers established by expert
panels (Timothy, 1988).
Patients and their relatives have different perspectives than
their professional carers. Undoubtedly patients with cancer
are more likely to opt for radical treatment with minimal
chance of benefit, than people who do not have cancer,
including medical and nursing professionals (Slevin et al.,
1990). If palliation is the accepted aim, good quality of life
becomes the top priority. However, in many clinical trials
this has not been assessed and it is acknowledged that
whereas quality of life is rarely improved by treatment that
does not lead to tumour response, the latter may not cor-
relate well with patient well-being. Quality of life as judged
by patients themselves is different from that as assessed by
their doctors and nurses (Slevin et al., 1988). Nevertheless,
physical function, mood, physical symptoms and social sup-
port are the key elements in assessment, and these should be
monitored from diagnosis, through treatment and in 'ter-
minal' illness (Mor, 1987). In the latter phase the 'process' of
care rather than the 'outcome' must be assessed and this is
not straight-forward since care is more than usually multidis-
ciplinary and specific measures to focus on the perception of
the relatives rather than the person who is dying are also
needed (NHS Management Executive, 1991). Quality must be
the endpoint however (Ahmedzai, 1990) and this should be
assessed against the background of cost effectiveness and
limited resources. Palliative care can be undertaken in hos-
pital (including specialist cancer treatment centres), in hos-
pices or at home. Most people would prefer to die at home
(Dunlop et al., 1989) with a hospice as second choice; despite
this about three quarters die in hospital, and proportionately
few die in a hospice. Superficially, home care would appear
to be a cheap option for the NHS but if the increased work
load of the community team, the higher cost of community
prescribing, the specialist care services required and the extra
care and support needed for the patient's family are taken
into account home care costs can be as high as those in
institutions (Gray et al., 1987). Hospice care represents excel-
lent value to the NHS which provides overall less than half
ofthe funding ofhospices. Bed costs in hospices vary accord-
ing to size but are probably about the same as those of an
acute general hospital (Hill & Oliver, 1988, Dunt et al.,
1989), which currently average about £110 per day (with the
caveat that there are many variables in different settings; for
example, this figure is likely to be higher in larger and
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specialist institutions). If in fact there is little to choose
cost-wise between hospital, home and hospice, then in the
ideal situation the choice of where to die should be made by
the patients themselves, though inevitably any clinical de-
cision will be affected by what is locally available.
Much work still needs to be done on consensus manage-
ment, audit and quality assurance (Standing Medical Ad-
visory Committee, 1990) in the field of palliation. Initiatives
such as The Trent Region Palliative Care Centre should serve
as development foci for all facets of the management of
incurable disease and lead and stimulate effective research
and teaching in this multidisciplinary field.
Oncologists and palliative care physicians, or hybrids of
the two (McIllMurrary, 1987), should lead the way and work
together in initiating the new NHS changes to the future
benefit of our patients (Hancock, in press).
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